Search
nirmatrelvir
Indications:
- used in combination with ritonavir in Paxlovid to treat early outpatient Covid-19
Mechanism of action:
- viral protease inhibitor
- expected in vitro activity against all clinically significant SARS-CoV-2 variants as of December 22, 2021
Notes:
- emergence of SARS-CoV-2 strains resistant to nirmatrelvir after treatment with Paxlovid is rare, independent of virologic rebound [2]
General
antiviral agent
References
- McNamara D
FDA Authorizes Pfizer Antiviral Pill for COVID-19.
Medscape. December 22, 2021
https://www.medscape.com/viewarticle/965398
- Tamura TJ, Choudhary MC, Deo R et al
Emerging SARS-CoV-2 Resistance After Antiviral Treatment.
JAMA Netw Open. 2024 Sep 3;7(9):e2435431.
PMID: 39320890 PMCID: PMC11425144 Free PMC article.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824050
Component-of
Paxlovid (nirmatrelvir/ritonavir)